Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a “game-changer” study. Patients with advanced ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Patients with advanced bladder cancer treated with an immunosuppressant drug were a third less likely to see the disease ...

Salk scientists have found that eliminating the bile acid-producing protein BAAT and supplementing with the bile acid UDCA ...

Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder cancer are significantly improved by adding an immunotherapy drug to before ...

Objective response rate: The percentage of patients whose cancer shrinks or disappears after treatment. Bacillus Calmette-Guérin (BCG): A type of immunotherapy used to treat bladder cancer by ...